ARTIVA BIOTHERAPEUTICS
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
ARTIVA BIOTHERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2019-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.artivabio.com
Total Employee:
51+
Status:
Active
Contact:
858-267-4467
Email Addresses:
[email protected]
Total Funding:
198 M USD
Technology used in webpage:
Person Schema Google Google Cloud
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Akero Therapeutics
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Visen Pharmaceuticals
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Wellington Management
Wellington Management investment in Series B - Artiva Biotherapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Artiva Biotherapeutics
5AM Ventures
5AM Ventures investment in Series B - Artiva Biotherapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Artiva Biotherapeutics
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - Artiva Biotherapeutics
Acuta Capital Partners
Acuta Capital Partners investment in Series B - Artiva Biotherapeutics
Franklin Templeton
Franklin Templeton investment in Series B - Artiva Biotherapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Artiva Biotherapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Artiva Biotherapeutics
Green Cross Holding
Green Cross Holding investment in Series B - Artiva Biotherapeutics
Key Employee Changes
Official Site Inspections
http://www.artivabio.com Semrush global rank: 4.8 M Semrush visits lastest month: 1.85 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Artiva Biotherapeutics"
Artiva's Exectives, Board of Directors and Scientific Advisors
Leadership. Our proven executive team brings deep, diverse cell therapy experience and is committed to developing safe, effective, and accessible NK cell therapies to patients.See details»
Artiva Biotherapeutics: NK Cell Therapy for Autoimmune Disease …
Artiva Biotherapeutics: Unlocking NK Cell Therapy for Autoimmune Disease and Cancer. The past decade has seen meaningful advances in cell therapy, with dramatic rates of clinical response …See details»
Artiva Biotherapeutics - Crunchbase Company Profile …
Contact Email [email protected] Phone Number 858-267-4467 Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the …See details»
Contact Us - Artiva Biotherapeutics
Artiva Biotherapeutics. 5505 Morehouse Drive, Suite 100 San Diego, California, 92121 1.858.267.4467. media @artivabio.com ; bd @artivabio.com ; careers @artivabio.com ...See details»
Working at Artiva Biotherapeutics - Glassdoor
Apr 16, 2022 Mission: At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, …See details»
Artiva Biotherapeutics, Inc. - Governance - Governance Documents
5505 Morehouse Drive, Suite 100 San Diego, California 92121. 1.858.267.4467 [email protected]See details»
Artiva Biotherapeutics - Craft
Oct 29, 2024 Artiva Biotherapeutics is a company that develops off-the-shelf cell therapies designed to treat hematologic malignancies or solid tumors. Its pipeline of targeted product …See details»
Careers at Artiva - Artiva Biotherapeutics
The Artiva team works closely together in effort to meet business objectives with a unique blend of area expertise coupled with excellent people skills. Motivation levels are very high and the collaborative discussions that take place daily …See details»
Artiva Biotherapeutics, Inc. - Governance - Committee Composition
5505 Morehouse Drive, Suite 100 San Diego, California 92121. 1.858.267.4467 [email protected]See details»
Artiva Biotherapeutics - VentureRadar
Develops innovative NK cell therapies, achieving FDA clearance for the first IND treatment for lupus nephritis in autoimmune diseases. " Artiva Biotherapeutics is advancing a pipeline of off …See details»
Artiva - 2025 Company Profile, Funding & Competitors - Tracxn
May 13, 2025 Artiva has raised a total funding of $198M over 3 rounds. Its first funding round was on Feb 2019. Its latest funding round was a Series B round on Feb 22, 2021 for $120M. …See details»
Artiva Biotherapeutics, Inc. - Artiva Biotherapeutics Appoints …
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) - Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and …See details»
Artiva announces terms for its second IPO attempt
Jul 16, 2024 After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.See details»
NK Cell Therapies for Autoimmune Disease and Cancer
Mechanism of Action. Many autoimmune diseases occur when autoreactive B-cells produce autoantibodies that target the body’s own healthy cells and tissues, and peer-reviewed clinical …See details»
Artiva Biotherapeutics, Inc. - Investor Relations
Apr 28, 2025 5505 Morehouse Drive, Suite 100 San Diego, California 92121. 1.858.267.4467 [email protected]See details»
Artiva Biotherapeutics Announces Promising Data for AlloNK
Apr 28, 2025 Artiva Biotherapeutics, Inc. announced that it will present new longer-term Phase 1/2 data for its AlloNK® cell therapy in patients with relapsed/refractory B-cell non-Hodgkin …See details»
Artiva Biotherapeutics, Inc. - Artiva Biotherapeutics Reports Full …
Mar 24, 2025 Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued …See details»
Artiva Biotherapeutics, Inc. - Artiva Biotherapeutics Reports Third ...
Nov 12, 2024 Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data …See details»
In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T ...
Feb 6, 2025 Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands …See details»
In the News - Artiva Biotherapeutics
News from Artiva for NK cell therapy for the treatment of autoimmune diseases and cancerSee details»